Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockMiser who wrote (649)	5/7/1999 3:44:00 PM
From: Dan Hamilton	Read Replies (1) of 2344

I have just started to follow Biomira, and I have a question relating to Biotechs in general. Obviously the further along a drug is in trials, the lower the risk to investors. Analysts typically try to do a risk adjusted rate of return calculation, discounting future potential profits by the number of years and probability of success/failure. I have seen statistics somewhere that suggest 2/3 of drugs that enter Phase I successfully pass, and 90% of those that pass Phase III ultimately get FDA approval. Does anyone know what the statistics are for Phase II and Phase III?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next